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Abstract Published data on the association between
DNA methyltransferase (DNMT) 3B -149C/T polymor-
phism and cancer risk remain inconclusive. To derive a
more precise estimation for this association, we performed
a meta-analysis of 5,903 cancer cases and 8,132 controls
from 22 published case–control studies. We used odds
ratios (ORs) with 95 % confidence intervals (CIs) to assess
the strength of the association. Our meta-analysis sug-
gested that DNMT3B -149C/T polymorphism was asso-
ciated with the risk of head and neck cancer under
heterozygote comparison (OR 0.73, 95 % CI 0.59–0.90)
and dominant model (OR 1.75, 95 % CI 0.62–0.92),
although no evidence of association between DNMT3B
-149C/T polymorphism and cancer risk was observed as
we compared in the pooled analyses (homozygote com-
parison: OR 0.96, 95 % CI 0.86–1.09; heterozygote com-
parison: OR 1.07, 95 % CI 0.86–0.32; dominant model:
OR 1.03, 95 % CI 0.85–1.25; recessive model: OR 0.93,
95 % CI 0.8–1.08). More studies are needed to detect
DNMT3B -149C/T polymorphism and its association with
cancer in different ethnic populations incorporated with
environment exposures in the susceptibility of different
kinds of cancer.
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Introduction
DNA methylation is a major epigenetic modification that
involves the addition of a methyl group to the 50 position of
a cytosine in a CpG dinucleotide, which is catalyzed by a
family of DNA methyltransferases (DNMTs) including
three activated forms (DNMT1, DNMT3A and DNMT3B)
in human [1, 2]. Aberrant DNA methylation is one of the
most consistent epigenetic changes observed in human
cancers [3]. DNMT1 is a maintenance DNA methyltrans-
ferase, whereas DNMT3A and DNMT3B are considered as
de novo methyltransferases because they can methylate
unmethylated and hemi-methylated DNA with equal effi-
ciency [4, 5]. A number of studies showed that DNMT3B
was up-regulated in several human cancers, demonstrating
that DNMT3B may play an important role in tumorigenesis
by contributing to the generation of aberrant DNA meth-
ylation [6–8].
The DNMT3B gene is assigned to chromosome 20q11.2
and contains a single C?T transition polymorphism
(C46359T) at a novel promoter region, -149 base pairs
from the transcription start site, which may result in greatly
increased promoter activity of the gene [9]. A number of
single-nucleotide polymorphisms (SNP) in the gene have
been described in the literature, of which a common SNP -
149C/T (rs2424913) in the promoter region of the DNMT3B
is known to regulate its expression [10]. Recently, a variety
of molecular epidemiological studies have been conducted
to examine the association between DNMT3B -149C/T
polymorphism and cancer susceptibility [11–31], but the
results remain inconclusive. Therefore, the association
between DNMT3B -149C/T polymorphism and cancer risk
requires further investigation.
Considering the relatively small sample size in most
studies, it is possible to perform a quantitative synthesis of
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the evidence with rigorous methods. Here, we performed a
meta-analysis on 22 published case–controls to derive a
more precise evaluation of the association between
DNMT3B -149C/T polymorphism and cancer risk.
Materials and methods
Identification and eligibility of relevant studies
A systematic literature search was performed using Pub-
Med, Medline, EMBASE and Chinese National Knowl-
edge Infrastructure (CNKI), covering all articles published
up to October 2014. We used the following terms:
‘‘DNMT3B,’’ ‘‘polymorphism,’’ ‘‘rs2424913’’ and ‘‘can-
cer’’. References of the retrieved publications were also
screened. All eligible studies were retrieved, and their
bibliographies were checked for other relevant publica-
tions. Only published studies with full-text articles were
included. When overlapping articles were found, we only
included the publications that reported the most extensive
information.
Inclusion criteria
The inclusion criteria were as follows: (1) published in
English or in Chinese; (2) case–control studies of cancer
with DNMT3B -149C/T polymorphism; (3) supply the
available genotype frequencies in cancer cases and con-
trols; and (4) sufficient published data for estimating an
odds ratio (OR) with 95 % confidence interval (CI).
Data extraction
Two investigators independently (Jing Zhu and Songtao
Du) reviewed the articles to exclude irrelevant and over-
lapping studies. The results were compared, and disagree-
ments were resolved by discussion and consensus.
We extracted the following information from each study:
first author’s surname, year, ethnicity, tumor type, defini-
tion of cases, characteristics of controls, validity of the
genotyping method, and the number of cases and controls
for each genotype.
Statistical analysis
OR and 95 % CI were used to assess the strength of
association between DNMT3B -149C/T polymorphism
and the risk of cancer under homozygote comparison (CC
vs. TT), heterozygote comparison (CT vs. TT), dominant
(CC/CT vs. TT) and recessive (CC vs. CT/TT) genetic
model comparison. The significance of the combined OR
was determined by the Z test, in which P \ 0.05 was
considered significant. Stratified analyses were also per-
formed by cancer types, ethnicities, and sources of con-
trols. The Chi-square-based Q statistic test was performed
to evaluate the between-study heterogeneity of studies. If
P \ 0.1, between-study heterogeneity was considered to be
significant [32]. When the effects were assumed to be
homogenous, the fixed effects model based on Peto method
was used, otherwise, the random effects model based on
Mantel–Haenszel method was applied. We also used the
statistic of I2 to efficiently test for the heterogeneity, with
I2 \ 25 %, 25–75 % and [75 % to represent low, moder-
ate and high degree of inconsistency, respectively [33].
Funnel plots were used to access the potential publication
bias by the method of Egger’s linear regression test [34].
All analyses were performed by Stata (version 10.0, Stata
Corporation) and Review Manager (version 5.0.0, The
Cochrane collaboration), using two side P values.
Results
Characteristics of studies
Twenty two case–control studies including 5,903 cancer
cases and 8,132 controls met the including criteria. The
study characteristics were listed in Table 1. Most of cases
in the studies were histologically diagnosed, and most of
the controls were selected from healthy population. Fifteen
studies used frequency-matched controls to the cases by
age, sex, residence or ethnicity. A classic polymerase chain
reaction–restriction fragment length polymorphism assay
was performed in all studies (Table 1).
Main results
The evaluation of association between DNMT3B -149C/T
polymorphism and cancer risk is presented in Table 2.
There was no significant association between DNMT
-149C/T polymorphism and the risk of cancer (CC vs. TT:
OR 0.96, 95 % CI 0.86–1.09; P = 0.1, I2 = 34 % for het-
erogeneity). In the stratified analysis by cancer type,
DNMT3B -149C/T polymorphism was relative with a
significantly increased risk of head and neck cancer in two
tested models (CT vs. TT: OR 0.73, 95 % CI 0.59–0.9;
P = 0.33, I2 = 0 % for heterogeneity; CC/CT vs. TT: OR
0.76, 95 % CI 0.61–0.93; P = 0.3, I2 = 7 % for hetero-
geneity; Fig. 1). However, no significant elevated risk of
colorectal cancer, gastric cancer, hepatocellular cancer,
breast cancer and other cancers with this polymorphism
were shown in overall comparisons. At the same time, we
failed to find significant main effects for DNMT3B -149C/
T polymorphism on cancer risk in different genetic models
when stratified according to ethnicity or sources of controls.
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Test of heterogeneity
There was significant heterogeneity for recessive model
comparison (CC vs. CT/TT: Pheterogeneity = 0.01), for het-
erozygote comparison (CT vs. TT: Pheterogeneity \ 0.001)
and for dominant model comparison (CC/CT vs. TT:
Pheterogeneity \ 0.001), but not for homozygote comparison
and (CC/TT: Pheterogeneity = 0.1). Then, we assessed the
source of heterogeneity for homozygote comparison by
cancer type, ethnicity and source of controls. As a result,
cancer type (v2 = 7.04, df = 4, P = 0.13), ethnicity
(v2 = 3.36, df = 3, P = 0.34) and source of controls
(v2 = 2.56, df = 1, P = 0.11) were not found to contribute
to substantial heterogeneity.
Sensitivity analysis
Sensitivity analysis was performed by sequential omission
of individual studies in whole subjects and subgroups,
respectively. For DNMT3B -149C/T, the significance of
Fig. 1 Meta-analysis with a
fixed effects model for the ORs
of cancer risk associated with
DNMT3B -149 C/T (CC/CT
vs. TT)
Med Oncol (2015) 32:399 Page 5 of 8 399
123
pooled ORs was influenced evidently by individual study
on the whole population or subgroup analysis of cancer
type and ethnicity. In the cancer type subgroup analysis,
the study of Jones et al. [13] was the main originators of
heterogeneity in the colorectal cancer. When the study was
excluded, heterogeneity was significantly decreased (CC
vs. CT/TT: Pheterogeneity = 0.94, I
2 = 0 %). Similarly,
when study by Mostowska et al. [31] was excluded, het-
erogeneity was also decreased in other type cancer (CC vs.
CT/TT: Pheterogeneity = 0.34, I
2 = 11 %). Additionally, in
the ethnicity subgroup analysis, sensitivity analyses sug-
gested that the study [28] was the main originator of het-
erogeneity in Asian. After exclusion of this study,
heterogeneity was significantly decreased (CT vs. TT:
Pheterogeneity = 0.37, I2 = 8 %; CC/CT vs. TT: Pheter-
ogeneity = 0.37, I2 = 0 %).
Publication bias
Funnel plots are shown in Fig. 2 for dominant model.
Arrangement of data points did not reveal any evidence of
obvious asymmetry. Formal evaluation using Egger’s
regression asymmetry tests for dominant model and the
result still did not show any evidence of publication bias
(t = 0.25, P = 0.80).
Discussion
The present meta-analysis, including 5,903 cancer cases
and 8,132 controls from 22 published case–control studies,
showed that the DNMT3B -149C/T was not associated
with cancer risk. When stratified by different types of
cancer, we found an association between DNMT3B
-149C/T polymorphism and head and neck cancer risk
under heterozygote comparison and dominant model, but
there are only two studies in analysis with limited sample
size; therefore, the result should be interpreted with cau-
tion. Given the important roles of DNMT3B in cancer risk,
it was biologically possible that DNMT3B polymorphism
is associated with the risk of cancer by increasing
DNMT3B promoter activity that modulated an aberrant de
novo methylation of CpG islands in some tumor suppressor
genes [4]. Studies on the functionality of this polymor-
phism might contribute to a better understanding of tumor
biology and behavior and help us to predict the genetic
susceptibility of cancer and choose therapies in an indi-
vidual manner. However, DNMT3B -149C/T polymor-
phism did not increase the risk of colorectal cancer, gastric
cancer, breast cancer and hepatocellular carcinoma in
overall population. The probability may be that different
types of cancer may have different mechanism of carci-
nogenesis. The differences in genetic background and/or
environmental exposure may result in different frequency
of -149 C/T genotype in healthy individuals from distinct
ethnicities; however, in subgroup analysis by ethnicity, we
also did not find that DNMT3B -149C/T was associated
with ethnicity. It is likely that the small sample size may
have insufficient statistical power to detect a real effect.
Therefore, more studies based on large population and
more different ethnicity should be conducted to further
examine this association.
Heterogeneity is a potential problem when interpreting
the results of all meta-analysis. Although we minimized the
likelihood by performing a careful search for published
studies, using strict criteria for study inclusion, precise data
Fig. 2 Funnel plot for
publication bias of the meta-
analysis of cancer risk and
DNMT3B -149C/T
polymorphism (CC/CT vs. TT)
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extraction and careful data analysis, significant between-
study heterogeneity existed in most comparisons. After
subgroup analysis by cancer types, ethnicity and source of
controls, the heterogeneity was effectively decreased, but
significant heterogeneity still existed. Thus, we choose to
use random effects model, when I2 value for heterogeneity
test is \50 %. The reason might be that different genetic
backgrounds and the environment existed among different
ethnicities and individuals.
Numbers of SNPs, however, were frequently investi-
gated in the former studies to evaluate the association
between DNMT3B polymorphisms and cancer in diverse
populations. There might be some other SNPs in DNMT3B
associated with risk of cancer. Lee et al. [35] found C
alleles of DNMT3B contributed to the susceptibility of
lung cancer in Korean population. Some other SNPs of
DNMT3B, such as -579 G/T and -283 T/C, were also
researched by some studies on their association with cancer
risk [11, 12, 14, 19, 36, 37]. However, there were only a
very limited number of studies available for some SNPs
and therefore not having enough statistical power to
explore the real association.
Some other limitations in our meta-analysis should be
acknowledged. Firstly, controls were not uniformly
defined, while our result was based on unadjusted esti-
mates. Secondly, in the subgroup analyses, the sample
size of different types of cancer was relatively small, such
as lung cancer, ovarian cancer and prostate cancer not
having enough statistical power to explore the real asso-
ciation. Thirdly, only English and Chinese language
studies were included in this meta-analysis might have led
to publication bias, and the exclusion of unpublished data
was generally associated with an overestimation of the
true effect.
In conclusion, our meta-analysis suggested that
DNMT3B -149C/T polymorphism was not related to
overall cancer risk, whereas there was an association
between DNMT3B -149C/T polymorphism and head and
neck cancer risk under heterozygote comparison and
dominant model. Larger samples among different popula-
tions, especially more sophisticated gene–gene and gene–
environment interactions should be considered in future
studies, which should lead to better, comprehensive
understanding of the association between DNMT3B
-149C/T polymorphism and cancer risk.
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